Stayble Therapeutics AB announces the outcome of the exercise of warrants of series TO1

04 Dec 2020 Regulatory

In total, 7,122 warrants were exercised, corresponding to approximately 0.3 percent of the outstanding warrants, for subscription of 7 122 shares at a subscription price of SEK 12.30 per share. Through the exercise of these warrant, Stayble will receive approximately SEK 88 thousand before issuing costs.

Background

Stayble Therapeutics AB carried out, during the first quarter of 2020 in conjunction to the listing on Nasdaq First North Growth Market, an issue of units where one unit consisted of one newly issued share and one warrant free of charge. Each warrant gives the right to subscribe one new share in the company.

The subscription period for exercise of the warrants lasted from November 17, 2020 up to and including December 1, 2020. The subscription price of the warrant was set to SEK 12.30 on November 16, 2020

Exercised warrants have been replaced with interim shares (IA) pending registration with the Swedish Companies Registration Office. The conversion of interim shares to common shares is estimated to happen within approximately 2 weeks.

Complete terms and conditions for the warrants are available on the Company’s website, www.staybletherapeutics.com.

Number of shares and share capital

Through the exercise of the warrants, the number of shares in Stayble increases by 7,122 shares, from 6,916,340 to 6,923,462 shares. The share capital will increase by SEK 925.86, from SEK 899,124.2 to SEK 900,050,06.

For existing shareholders who did not exercise any warrants of series TO1, the dilution amounts to approximately 0.1 percent.

Advisers

Mangold Fondkommission AB is the financial adviser and Advokatfirmaet Schjødt AS, filial is the leagel adviser to Stayble regarding the warrents.

For more information

Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se

+46 730 808 397

This information is such that Stayble Therapeutics AB is required to make public in accordance with the EU's Market Abuse Regulation (MAR). The information was made public by the Company's contact person above on December 4, 2020 at 08.00 CET

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company’s Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail ca@mangold.se